Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

U.S. Marine vet, detained in Russia since 2022, hospitalized in serious condition

Robert Gilman, 32, is being held at a Russian hospital in what his advocate, Eric Lebson of Global Reach, described as a "dissociative stupor."

A former U.S. Marine who has been held in Russia since 2022 is currently hospitalized in critical condition, according to his family's advocate. Robert Gilman, 32, is being treated at a Russian hospital in a state of apparent dissociation, with medical staff providing him through a nasal tube. Eric Lebson, representing Gilman's family through Global Reach, claims the Russian authorities have subjected him to mistreatment, including harassment, forced exercise lasting up to 16 hours, and the administration of psychotropic medications.

Lebson also alleges that Gilman was coerced into fighting in Ukraine. While CBS News has not independently confirmed these allegations, and Russian officials have not publicly responded, Lebson asserts that the situation with Gilman is unprecedented compared to any other American currently detained in Russia. He fears the outcome could mirror that of Otto Warmbier, who died after being detained in North Korea.

The U.S. State Department has expressed deep concern for Gilman's health and ongoing detention, stating that the Trump administration has repeatedly raised his case with Russian authorities and requested his release on humanitarian grounds. A State Department spokesperson said the White House remains deeply concerned and will closely monitor Gilman's case.

Written by urgent.news from CBS News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at cbsnews.com →

More in Health & Medicine

FDA approves first drug for full range of narcolepsy symptoms

The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults. Orzeyful marks the first medication approved for the full range of symptoms associated with narcolepsy type 1 and is the first approved drug to directly target the loss of orexin signaling that causes the disease.

More from Thursday 6 August →